



Pharmacology - Efficacy studies - Mechanistic studies - Molecular screening

The heart of expertise

Preclinical CRO services specialized in cardiovascular diseases and cardiometabolic complications

THE COMPANY

- ❖ Cardiomedex is a CRO specialized in cardiovascular diseases founded in 2011
- ❖ We provide value-added expertise and ensure high-quality standards to deliver highly reliable results
- ❖ We offer a wide variety of services ranging from gold standard integrated patho-physiological models to isolated organs and cells.

MANAGEMENT TEAM



Thierry Sulpice, PhD

CEO/CSO, Founder

Member of Scientific Advisory Board

9 years at Sanofi–Aventis / Drug discovery optimization and preclinical development for projects targeting the cardiometabolic syndrome.

PhD in Physiology and Pharmacology University of Grenoble, France.

Founder and CEO/CSO of Physiogenex since 2001

Caroline Dubroca, PhD

Director, Scientific Operations & Research Development

Member of Scientific Advisory Board

Over 15 years' experience in pharmacology

Preclinical development of drugs targeting cardiovascular & metaobolic diseases.

PhD in Biology and Pharmacology of vascular homeostasis, Paris VII University, France.




OUR SERVICES

Physiopathological models

- Heart failure with reduced (HFrEF) or preserved ejection fraction (HFpEF)
- Myocardial infarction - Cardiac hypertrophy – Hypertension
- Anthracycline cardiotoxicity - Sepsis
- Cardiometabolic models (NASH-Diabetes-Metabolic syndrome)
- Cardiorenal models

Functional exploration & characterization

- Echocardiography / Invasive left ventricle function (Millar probes)
- Telemetry / ECG & Heart rate variability
- Exercise test with Treadmill
- Histology, biomarkers dosage, gene & protein expression



Ex vivo / In vitro assays

- Myograph vascular reactivity & Endothelial function
- Isolated Langendorff heart
- Cardiomyocytes calcium transients and contractility (IonOptix)

Molecular screening (BRET technology)

- Hit to lead and lead optimization
- Receptor research
- Signalling pathways

Our partners




Physiogenex is a preclinical CRO specialized in metabolic disorders. Together, our two companies can provide a fully integrated approach to cardiometabolic diseases, enabling us to design large-scale studies to evaluate the effect of drug candidates on both cardiac and metabolic functions in predictive and integrative models.



Team research focuses on cardiomyocyte morphology & cardiac tissue organization and has also extensive expertise in cell surface receptor pharmacology with a specific emphasis on cardiac GPCRs that are explored using the BRET technology.

They trust us





CARDIOMEDEX SAS

www.cardiomedex.com

contact@cardiomedex.com